Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 21, 2021updated 07 Jan 2022 8:49am

FDA grants 510(k) clearance for Neuronetics’ MT Cap technology

Leveraging NeuroStar’s floating coil locking system, the MT Cap technology makes determining motor thresholds seamless.

The US Food and Drug Administration (FDA) has granted 510(k) approval to Neuronetics for its MT Cap technology for Neurostar Advanced Therapy for Mental Health.

Neurostar Advanced Therapy for Mental Health is a non-invasive, non-drug, transcranial magnetic stimulation therapy intended for treating people suffering with major depressive disorder.

NeuroStar targets the depression source and helps to activate the natural functioning of the neurotransmitters in the brain using a non-invasive magnetic field.

Besides providing the starting location of a target, the MT Cap technology offers ‘step-by-step map’ to guide the identification process to motor threshold (MT) of a patient and cuts down several steps during the initial evaluation for NeuroStar.

Leveraging NeuroStar’s floating coil locking system, the MT Cap technology is claimed to make mapping and determining motor thresholds seamless.

Neuronetics clinical affairs and medical operations vice president Cory Anderson said: “We’re delighted to bring to market this latest in a series of technologies designed to make the motor threshold determination process simpler and more efficient for clinicians.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“We appreciate the ongoing collaboration with FDA that enabled a quick and efficient review process.”

The process of determining and locating MT in a patient takes up to 30 minutes and is a critical aspect of the treatment process.

Neuronetics noted that the combination of MT Cap technology with the Fast MT, which was recently launched, lead to an average time savings of about 40% during the MT determination process.

The company expects to begin a limited introduction of the technology in the weeks to come, with the country-wide rollout to begin in the first quarter of next year.

Last year, FDA granted breakthrough device designation for Neuronetics’s NeuroStar Advanced Therapy System to treat bipolar depression.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU